MedTrace Logo

CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

NCT04508205 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2020-08-12

No results posted yet for this study

Summary

Open-label multicenter study using CGB-400 Gel to reduce facial redness, bumps, and blemishes.

Conditions

  • Rosacea

Interventions

DRUG

CGB-400

BID application

Sponsors & Collaborators

  • ethica Clinical Research Inc.

    collaborator INDUSTRY

  • CAGE Bio Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-26
Primary Completion
2019-04-18
Completion
2019-04-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04508205 on ClinicalTrials.gov